Consequently, the treatment levels did not differ as much between RC and IT groups as was expected at study inception.
Major operations must not be expected at time of study begin, except for potential secondary resection of liver metastases.
Considering the smaller expected change in BMD (1 5%, for existing treatments) after only 12 months of treatment, we expected at best the study to show a trend for an effect of ch-OSA on BMD.
The mean age at diagnosis was lower than expected in this study.
It also provided a loose road map of topics to expect at future study sessions.
Focusing solely on those who dropped out (N = 19), the average time from enrollment to dropout was 48.7 days (Median: 54.5 days; range: 12.0 to 84.0 days); at the study level, they submitted 69.6% (1424/2046) of the diaries expected at the point in the study at which they dropped.
Data from this study are expected at the end of 2009.
Our results, surprisingly, show travel times that are much lower than we expected at the outset of our study.
However, 126 of 599 women in the 1988/89 cohort had received a full course of three doses of HPV vaccines, which was more than expected at the start of the study.
Overall the effect was perhaps less than expected (at least compared to a similar study by Nadkarni & Solano (2009) from Costa Rica).
